Truncation of the p300/CBP TAZ2 domain promotes tumor progression

Truncating mutations in the TAZ2 domain have been identified in several cancer types. Here, we show that truncation of p300/CBP at the TAZ2 domain inhibits tumor cell growth in vitro, while accelerating tumor progression in a xenograft mouse model.

Importantly, tumors harboring TAZ2 truncations are vulnerable to histone deacetylase inhibitors (HDACis). We performed transcriptomic analysis to investigate the molecular changes driven by TAZ2 truncation during tumor progression and in response to HDAC inhibition.